Emily Charlotte Cherney

USPTO Granted Patents = 18 (Patent Applications = 4)

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 2 (Patent Applications = 14)

Average Co-Inventor Count = 7.1

ph-index = 4

Forward Citations = 51(Granted Patents)

Location History:

Princeton, NJ (US) (2020 - 2022)
Newtown, PA (US) (2017 - 2023)

Company Filing History:

14 out of 3,685

Bristol-myers Squibb Compnay

patents

5 out of 8

Flexus Biosciences, Inc.

patents

1 out of 7

Syngene International Limited

patents

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12331045 - Substituted phenyl oxazolone compounds (2025-06-17),

2. 11649212 - Inhibitors of indoleamine 2,3-dioxygenase and methods of their use (2023-05-16),

3. 11351164 - Inhibitors of indoleamine 2,3-dioxygenase and methods of their use (2022-06-07),

4. 11337970 - Inhibitors of indoleamine 2,3-dioxygenase and methods of their use (2022-05-24),

5. 11203592 - Inhibitors of indoleamine 2,3-dioxygenase and methods of their use (2021-12-21),

6. 11066392 - Inhibitors of indoleamine 2,3-dioxygenase and methods of their use (2021-07-20),

7. 11066383 - Inhibitors of indoleamine 2,3-dioxygenase and methods of their use (2021-07-20),

8. 10689331 - IDO inhibitors (2020-06-23),

9. 10633342 - Inhibitors of indoleamine 2,3-dioxygenase and methods of their use (2020-04-28),

10. 10544099 - Inhibitors of indoleamine 2,3-dioxygenase and methods of their use (2020-01-28),

11. 10533014 - Immunoregulatory agents (2020-01-14),

12. 10399932 - Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer (2019-09-03),

13. 10206893 - Immunoregulatory agents (2019-02-19),

14. 10167254 - IDO inhibitors (2019-01-01),

15. 10106546 - Immunoregulatory agents (2018-10-23),

Title: Innovations by Emily Charlotte Cherney: A Pioneer in IDO Inhibitors

Introduction: Emily Charlotte Cherney, based in Newtown, PA, is an innovative inventor known for her significant contributions to the field of medicinal chemistry. With an impressive portfolio of 17 patents, she has made remarkable strides in developing compounds aimed at treating serious health conditions, including cancer and autoimmune diseases.

Latest Patents: Among her most recent inventions are compounds designed as inhibitors of indoleamine 2,3-dioxygenase (IDO). These groundbreaking patents include detailed formulations that can serve as potential medicaments for proliferative disorders like cancer, viral infections, and autoimmune diseases. Her work presents various compounds with specific configurations, unveiling new methodologies for treating these challenging conditions.

Career Highlights: Emily has had a dynamic career, notably working with renowned pharmaceutical companies such as Bristol-Myers Squibb Company and Flexus Biosciences, Inc. Her efforts in these organizations have focused on developing innovative therapies that leverage her extensive knowledge of enzymatic pathways and pharmacology.

Collaborations: Throughout her career, Emily has collaborated with esteemed colleagues, including James Aaron Balog and David K Williams. These partnerships have facilitated the exchange of ideas and further propelled advancements in her research, leading to impactful innovations in the field.

Conclusion: Emily Charlotte Cherney exemplifies the spirit of innovation in the medical field, particularly through her work on IDO inhibitors. With a strong foundation in research and collaboration, she continues to make significant contributions that hold promise for the treatment of various debilitating diseases, demonstrating the vital role of inventors in advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.